PepGen Inc. (PEPG)
NASDAQ: PEPG
· Real-Time Price · USD
4.80
-0.09 (-1.84%)
At close: Oct 16, 2025, 3:59 PM
4.72
-1.67%
After-hours: Oct 16, 2025, 07:37 PM EDT
-1.84% (1D)
| Bid | 4.77 |
| Market Cap | 157.44M |
| Revenue (ttm) | 1.49M |
| Net Income (ttm) | -96.92M |
| EPS (ttm) | -2.96 |
| PE Ratio (ttm) | -1.62 |
| Forward PE | -2.76 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 4.83 |
| Volume | 857,484 |
| Avg. Volume (20D) | 3,259,037 |
| Open | 4.89 |
| Previous Close | 4.89 |
| Day's Range | 4.60 - 4.99 |
| 52-Week Range | 0.88 - 9.15 |
| Beta | 1.97 |
| Ex-Dividend Date | n/a |
About PEPG
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PEPG
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PEPG stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+121.05%
PepGen shares are trading higher. The company anno...
Unlock content with
Pro Subscription
3 weeks ago
+36.41%
PepGen shares are trading higher after the company announced clinical data today from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose study in patients with myotonic dystrophy type 1.
3 weeks ago · businesswire.com
PepGen Announces Highest Mean Splicing Correction Reported in DM1 PatientsBOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of s...
